• Skip to main navigation
  • Skip to main content
  • Skip to Footer
  • Navigate Novartis
    • Patients
    • Healthcare Professionals
    • Media
    • Investors
    • Partners
    • ESG
    • Job Seekers
    • Clinical Trials
  • Coronavirus
  • Global
    • Novartis site directory
Novartis logo: a global healthcare company
  • Our Company
    • Our Leadership
      • Board of Directors
      • Executive Committee of Novartis
    • Our Approach
      • Strategy
      • Corporate Responsibility
      • Diversity & Inclusion
      • Partnering
      • People and Culture
    • Our Business
      • Global Product Portfolio
      • Innovative Medicines
      • Novartis Pharmaceuticals
      • Novartis Gene Therapies
      • Novartis Oncology
      • Sandoz
    • Media
      • Newsroom
      • News Archive
      • Multimedia Resources
      • Subscribe to Updates
    • Investors
      • Event Calendar
      • Financial Data
      • Share Data & Analysis
      • Shareholder Information
      • Environmental, Social & Governance
  • Our Focus
    • Disease Areas
      • Cancer
      • Cardiovascular, Renal and Metabolic Medicine
      • Immunology & Dermatology
      • Ophthalmology
      • Neuroscience
      • Respiratory
    • Platforms and Technology
      • Data and Digital
      • Cell & Gene Therapy
    • Novartis Stories
      • Discovery
      • From Our Labs
      • Access to Healthcare
      • Patient Perspectives
      • People and Culture
      • Live Magazine
  • Our Impact
    • Building Trust with Society
      • Corporate Responsibility
      • Ethical Standards
      • Access
      • Environmental Sustainability
    • Global Health
      • Malaria
      • Sickle Cell Disease
      • Chagas disease
      • Leprosy
      • Novartis Foundation
    • ESG Performance and Reporting
      • Materiality Assessment
      • Environmental, Social and Governance
      • Transparency and Disclosures
      • Positions on Key Topics
      • Statements on Key Issues
  • Our Science
    • Research & Early Development
      • Novartis Institutes for BioMedical Research
      • Research Disease Areas
      • Postdoc Program
      • Open Source Science
    • Drug Development at Novartis
      • Novartis Pipeline
      • Clinical Trials
      • Translational Medicine
      • Global Product Portfolio
    • Science Stories
      • Discovery
      • From Our Labs
  • Careers
    • Your Career
      • Global Career Search
      • Teams and Skills
      • Gene Therapies Careers
    • Working at Novartis
      • Diversity & Inclusion
      • People and Culture
      • Corporate Responsibility
    • Career Programs
      • Our Career Programs
      • Students and Scholars
      • Novartis Quantitative Sciences Hackathon
Search
Translating biology into medicine
  • TwitterTweet
  • FacebookShare
  • Share
    • Twitter
    • Facebook
    • LinkedIn
    • Email
    • Whatsapp
  • Jump to Comments
Stories/Discovery

Translating biology into medicine

Clinical trials lead to new insights into aging. Hear how NIBR is advancing healthy aging.

Apr 13, 2015

Over a lifetime, most of us learn to accept the physical decline that comes with aging. We slow down, our eyesight and hearing deteriorate, we’re more prone to illness and injury. And, yes, there’s the gray hair and wrinkles. But many aging people face the loss of normal, independent living as a result of their reduced mobility and sensory ability. Might we be able to intervene – through potential new medicines – in the biological pathways involved in aging?

It’s a biomedical mystery that has long fascinated former academic researcher and hospital physician Joan Mannick. But it was only after making the switch to the pharmaceutical industry and then joining the Translational Medicine group at the Novartis Institutes for BioMedical Research (NIBR) in 2010 that she was able to begin a serious pursuit of the answer.

“I got to Novartis and said to my boss: ‘How about we work on aging?’,” recalls Mannick, now Executive Director of NIBR’s New Indications Discovery Unit. “A lot of people in the field have talked about how great it would be if someone did a clinical trial, but no-one had the resources to do it. We were given resources to do one of the first clinical trials ever to see if we could impact the rate of aging in humans. Novartis supported me and we did it.”

Mannick’s pioneering clinical trial is an example of the autonomy and the scientific and financial resources granted to NIBR’s Translational Medicine scientists to advance the understanding of neglected diseases and change how they are treated. “There’s really a lot of freedom you are given to push boundaries and do the most exciting innovative research you can,” adds Mannick. “It's very rare.”

The 360-strong global Translational Medicine group brings research advances made in the lab into the clinic, where investigational treatments are tested in patients for the first time. And it’s this opportunity to make an immediate impact that Mannick’s Translational Medicine colleague and infectious disease researcher Florencia Pereyra Segal most likes about working in the translational space.

“I always wanted to do something that was meaningful for patients,” she says. “I realized that advancing knowledge in the lab, although very valuable, was not going to translate into a direct benefit to patients. I started looking at where I could have the most impact but still be very close to the science, which was what took me to medical school in the first place.”

Meanwhile, Chinweike Ukomadu, an expert in hepatology, values the learning and intellectual stimulation on offer in Translational Medicine. He says: “To be able to walk into a team meeting and know there are 11 other people there who know infinitely more than I do about what they do and I can learn from them – that makes coming to work really amazing every day.”

Learn more about career opportunities at NIBR.

Tags: 
Novartis Institutes for BioMedical Research, Scientific Discoveries, Careers, Clinical Trials
    • TwitterTweet
    • FacebookShare
    • Share
      • Twitter
      • Facebook
      • LinkedIn
      • Email
      • Whatsapp
    • Jump to Comments
  • Print
  • Save

Novartis Stories

View all

RNA strand
Discovery

Take a visual tour of medicines that target RNA

A kidney patient is smiling at the camera
Discovery

New hope for treating inflammatory diseases of the kidney

2D rendering of kidneys
Discovery

Predictive analytics could bring medicines to patients faster

You are here

  1. Home ›
  2. Stories ›
  3. Discovery

Novartis Global

  • Navigate Novartis

    • Patients & Caregivers
    • Healthcare Professionals
    • Investors
    • Media
    • Society & ESG
    • Partners
  • Contact Us

    • Global Contacts
    • Office Locations
    • For Investors
    • For Media
  • About Novartis

    • Our Company
    • Our Focus
    • Our Impact
    • Our Science
    • Our Stories
  • Our Portfolio

    • Global Product Portfolio
    • Global Clinical Pipeline
  • Careers

    • Career Search

Connect with Novartis

  • twitter
  • linkedin
  • youtube
  • facebook
  • instagram
Novartis Site Directory
© 2021 Novartis AG
  • Terms of Use
  • Privacy Policy
  • Contact Us
  • Site Map
  • Cookie Settings

This site is intended for a global audience.